Detalhe da pesquisa
1.
Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Blood
; 141(14): 1718-1723, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36563336
2.
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
N Engl J Med
; 379(24): 2330-2341, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380364
3.
Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.
Blood
; 131(23): 2594-2596, 2018 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695518
4.
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Haematologica
; 105(8): e404-e407, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31753931
5.
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Blood
; 119(15): 3413-9, 2012 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22374701
6.
Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantation.
bioRxiv
; 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38405731
7.
Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury.
JACC Basic Transl Sci
; 8(3): 340-355, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37034289
8.
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.
Acta Haematol
; 127(3): 135-42, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22249155
9.
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Blood Adv
; 6(2): 652-663, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625794
10.
ABCB6 RNA expression in leukemias--expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia.
Ann Hematol
; 93(3): 509-12, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23793916
11.
Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization.
Blood Adv
; 8(6): 1379-1383, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38190608
12.
Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells.
J Clin Invest
; 129(7): 2745-2759, 2019 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085833
13.
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
PLoS One
; 10(3): e0121912, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25822503
14.
Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide.
Mediterr J Hematol Infect Dis
; 3(1): e2011056, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22220253
15.
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
J Clin Oncol
; 28(24): 3866-71, 2010 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20644086
16.
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Leuk Lymphoma
; 50(12): 2092-5, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19925053